Levels of Growth Differentiation Factor 15 and Early Mortality Risk Stratification in Cardiogenic Shock - UTU Research Portal

A1 Refereed original research article in a scientific journal

Levels of Growth Differentiation Factor 15 and Early Mortality Risk Stratification in Cardiogenic Shock

Authors: Hongisto M., Kataja A., Tarvasmäki T., Holopainen A., Javanainen T., Jurkko R., Jäntti T., Kimmoun A., Levy B., Mebazaa A., Pulkki K., Sionis A., Tolppanen H., Wollert K.C., Harjola V.-P., Lassus J.; for the CardShock investigators

Publisher: Churchill Livingstone Inc.

Publication year: 2019

Journal: Journal of Cardiac Failure

Journal name in source: Journal of Cardiac Failure

Volume: 25

Issue: 11

First page : 894

Last page: 901

Number of pages: 8

ISSN: 1071-9164

DOI: https://doi.org/10.1016/j.cardfail.2019.07.003

Abstract

Background: The aim of this study was to assess the levels, kinetics, and prognostic value of growth differentiation factor 15 (GDF-15) in cardiogenic shock (CS).

Methods and Results: Levels of GDF-15 were determined in serial plasma samples (0–120 h) from 177 CS patients in the CardShock study. Kinetics of GDF-15, its association with 90-day mortality, and incremental value for risk stratification were assessed. The median GDF-150h level was 9647 ng/L (IQR 4500–19,270 ng/L) and levels above median were significantly associated with acidosis, hyperlactatemia, renal dysfunction, and higher 90-day mortality (56% vs 28%, P < .001). Serial sampling showed that non-survivors had significantly higher GDF-15 levels at all time points (P < .001 for all). Furthermore, non-survivors displayed increasing and survivors declining GDF-15 levels during the first days in CS. Higher levels of GDF-15 were independently associated with mortality. A GDF-1512h cutoff >7000 ng/L was identified as a strong predictor of death (OR 5.0; 95% CI 1.9–3.8, P = .002). Adding GDF-1512h >7000 ng/L to the CardShock risk score improved discrimination and risk stratification for 90-day mortality.

Conclusions: GDF-15 levels are highly elevated in CS and associated with markers of systemic hypoperfusion and end-organ dysfunction. GDF-15 helps to discriminate survivors from non-survivors very early in CS.